Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

Irene Chan has stepped down as deputy director of FDA's China office. She joined the office in 2009 as one of its first policy analysts, covering food safety. As deputy director, she worked closely with FDA’s Oncology Center of Excellence to develop a strategy for working with the agency’s counterparts in China on cancer product reviews to improve access to innovative therapies. An FDA newsletter announcing her departure did not reveal what’s next for Chan.

Galera Therapeutics Inc. said Christopher Degnan will join the cancer company as CFO, effective Oct. 21. Degnan was CFO at Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), where he is succeeded by A. Brian Davis.

Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) hired Paul Mendelman as interim CMO, replacing Wolfgang Dummer who has left the anti-infective therapy company for personal reasons. Mendelman was VP, medical at the Takeda Vaccines Inc. division of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), as well as a veteran of MedImmune Inc., where he managed the clinical development group for FluMist from 1996 to 2005.

Orphan kidney disease company Palladio Biosciences Inc. hired Marella Thorell as CFO. She was CFO, COO and an executive director of Realm Therapeutics plc, which was acquired by Essa Pharma Inc. (NASDAQ:EPIX) in July. The hire comes two months after Palladio hired Realm CEO Alex Martin for its CEO post.

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE